S2672
RTT - Patient experience and quality of life
ESTRO 2026
Oncology, Cork University Hospital, Cork, Ireland. 4 Co- founder/Director, ONCOpatient, Killarney, Ireland. 5 Cancer Research@UCC, University College Cork, Cork, Ireland Purpose/Objective: Radiotherapy (RT) is an effective but underutilized treatment option for patients with metastatic cancer1. While studies have examined RT’s impact on health- related quality of life (HRQOL) internationally, there is limited data on Irish patients2, furthermore the use of electronic smartphone applications in this setting has not been investigated. This study aims to explore the feasibility of the use of electronic patient-reported outcomes (ePROs) to assess HRQOL changes in Irish patients receiving RT. Material/Methods: A single-institution ethics approved observational study of patients receiving palliative intent radiotherapy utilized an ePRO smartphone application, ONCOpatient, to administer EORTC-QOL- C30 core questionnaire to patients/caregivers at 4- timepoints: baseline (TP1), final treatment (TP2), 4- (TP3) and 12 (TP4) -weeks-post-treatment was performed.Descriptive statistics were used to summarize baseline patient and treatment characteristics, Global Health Score (GHS) and application engagement and compliance. Results: From October 2024 to October 2025, 48 participants were consented (1 patient withdrew and 3 did not proceed to RT) with 44 included in this analysis. Overall app engagement was 50% (22/44), with compliance declining over time. Genito-urinary (30%), lung (25%) and breast (20%) cancers were the most common primary diagnosis, with a median time from diagnosis to RT treatment 19 (IQR 4-51) months. 50% (22/44) were RT naïve and 27% (12/44) had prior palliative RT. Most common indications for palliative RT were – symptomatic bone (41%) and brain metastases (34%), with 20Gy in 5 fractions (45%) and 8Gy in 1 fraction (25%) most commonly prescribed.GHS was available in 50% (22/44), 36% (16/44), 20% (9/44) and 11% (5/44) at TP 1, 2, 3 and 4 respectively. Mean (standard deviation) GHS was 56.8 (17.2), 54.2 (17.9), 62 (22.3) and 68.3 (13.3) at TP 1, 2, 3 and 4 respectively. Of those with scores available at baseline and 4-weeks (17%) post RT the mean change score from baseline was 4.2 (21.6) which was not clinically significant.Barriers identified to application engagement included licensing issues, syncing delays, difficulty locating assessment dates and limited provider engagement regarding patient identification and onboarding. Conclusion: Baseline GHS were similar to those reported by EORTC reference values3, also participants who continued to
symptoms may impact their quality of life (QoL), few studies have explored patient experiences more than a decade after treatment. Thus, this study aimed to explore how men experience their QoL more than 15 years after radiotherapy for prostate cancer. Material/Methods: This qualitative study included interviews with 16 men (aged 74-91 years) from the randomised HYPO-RT-PC trial (n = 1180), which compared conventional fractionation (2.0 Gy x 39 fx) with ultra-hypo- fractionated radiotherapy (6.1 Gy x 7 fx). Men with prostate cancer were enrolled between 2005-2015. An interview guide was developed in collaboration with a prostate cancer federation. Semi structured interviews were conducted by an oncology nurse and continued until data saturation was achieved. A content analysis was then performed. Throughout the analytical process, the authors collaboratively discussed the findings, codes and categories until consensus was reached. The study was reported in accordance with the COREQ guidelines. Results: Participants described various aspects of QoL as long- time survivors of prostate cancer. A central theme across all interviews was the process of adjusting to and accepting a new daily life. Most men reported good QoL, regardless of other health conditions. While follow-ups and PSA testing served as reminders of their cancer history, the disease was not a dominant concern in everyday life. Natural ageing and comorbidities influenced their well-being, as did the health of close family members. Conclusion: Adapting to and accepting life after treatment was a key factor in maintaining a good QoL among long-term prostate cancer survivors. Additionally, factors unrelated to the disease can significantly impact QoL, underscoring the importance for healthcare professionals being aware of and responsive to these aspects. Keywords: prostate cancer, long-term survivors, qualitative Digital Poster 3216 Feasibility of Electronic Patient-Reported Outcome Use to Assess Quality of Life in Irish Patients Receiving Radiotherapy for Metastatic Disease Kimya Ghaffarian 1 , Bojan Macanovic 2 , Micheal O’Cathail 3 , Seamus O’Reilly 2 , Orla Monaghan 3 , Jonathan Coffey 3 , Karen O’Meara 3 , Eoin O’Carroll 4 , Aisling Barry 3,5 1 Department of Radiation Oncology, School of Medicine, University College Cork, Cork, Ireland. 2 Department of Medical Oncology, Cork University Hospital, Cork, Ireland. 3 Department of Radiation
Made with FlippingBook - Share PDF online